congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
HER3-DXd
ACoP14 | November 5-8, 2023
Exposure-response analyses of efficacy and safety of patritumab deruxtecan in cancer patients
Poster
Dato-DXd
ACoP14 | November 5-8, 2023
Exposure-response analysis of stomatitis associated with datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer
Poster
HER3-DXd
ACoP14 | November 5-8, 2023
Integrated population pharmacokinetic analysis of conjugated and unconjugated payload of patritumab deruxtecan in cancer patients